Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S decreased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 51.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,514 shares of the company's stock after selling 4,719 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Henry Schein were worth $312,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in HSIC. Lyrical Asset Management LP purchased a new position in Henry Schein during the fourth quarter worth about $126,655,000. Norges Bank acquired a new stake in shares of Henry Schein in the fourth quarter worth approximately $103,301,000. National Bank of Canada FI grew its holdings in Henry Schein by 102.4% in the fourth quarter. National Bank of Canada FI now owns 1,084,511 shares of the company's stock valued at $75,048,000 after purchasing an additional 548,561 shares during the period. Raymond James Financial Inc. acquired a new position in Henry Schein during the fourth quarter worth approximately $34,720,000. Finally, Clarkston Capital Partners LLC boosted its holdings in shares of Henry Schein by 24.8% in the 4th quarter. Clarkston Capital Partners LLC now owns 1,744,225 shares of the company's stock valued at $120,700,000 after purchasing an additional 346,420 shares during the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Stock Down 1.8 %

HSIC stock traded down $1.19 during trading on Wednesday, reaching $64.97. The stock had a trading volume of 1,059,826 shares, compared to its average volume of 1,618,912. The firm has a fifty day moving average price of $68.49 and a 200 day moving average price of $71.68. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $7.96 billion, a P/E ratio of 26.74, a PEG ratio of 2.13 and a beta of 0.84. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $82.49.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter last year, the firm posted $0.66 EPS. The company's revenue was up 5.8% compared to the same quarter last year. On average, equities analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Insider Activity

In other news, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now owns 62,688 shares of the company's stock, valued at approximately $4,460,251.20. This trade represents a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Philip A. Laskawy sold 2,604 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the sale, the director now owns 24,805 shares in the company, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on HSIC. Jefferies Financial Group lifted their target price on Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and raised their price target for the company from $69.00 to $84.00 in a report on Monday, January 6th. UBS Group dropped their price objective on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research report on Wednesday, February 26th. Wells Fargo & Company started coverage on shares of Henry Schein in a report on Friday, February 14th. They set an "equal weight" rating and a $80.00 target price on the stock. Finally, Piper Sandler lowered their price target on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a report on Wednesday. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Henry Schein currently has an average rating of "Moderate Buy" and an average target price of $80.20.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.